Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Clinical Pharmacology Publications – 2014

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995

  • Zhang M, Moore GA, Everts R, Begg EJ. Determination of total and free concentration of flucloxacillin and cefazolin in human plasma by liquid chromatography/tandem mass spectrometry. J Anal Bioanal Tech 2014; 5(1), 1-9 [Abstract]
  • Roberts RL, Wallace MC, Seinen ML, Barclay ML, et al. PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. Am J Gastroenterol 2014; 109, 925-7 [Abstract]
  • Korell J, Duffull SB, Dalrymple JM, Drake J, Zhang M, Barclay ML, Stamp LK. Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. Br J Clin Pharmacol 2014; 77(3), 493-7 [Abstract]
  • Chin PKL, Wright DFB, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 2014; 78(3), 599-609 [Abstract]
  • Chin PKL, Patterson DM, Zhang M, Jensen BP, Wright DFB, Barclay ML, Begg EJ. Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol 2014; 78(3), 630-8 [Abstract]
  • Sanderson C, Quinn SJ, Agar M, Doogue M, et al. Pharmacovigilance in hospice/palliative care: net effect of gabapentin for neuropathic pain. BMJ Support Palliat Care 2014 [Abstract]
  • Chin PKL, Wright DFB, Florkowski CM. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation A Re-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis (letter). Circulation 2014; 130(22), e194 [Abstract]
  • Pan S, Stamp LK, Duffull SB, Barclay ML, Zhang M, et al. Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet 2014; 53(12), 1161-70 [Abstract]
  • Radhakutty A, Shen J, Hooper AJ, Miller SA, Burnett JR, Mah PM, Doogue MP. Quantification and genotyping of lipoprotein lipase in patients with diabetic lipaemia. Diabet Med 2014; 31(12), 1702-7 [Abstract]
  • Chin PKL, Wright DFB, Zhang M, Wallace MC, Barclay ML, Begg EJ, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystanin C. Drugs R D 2014; 14(2), 113-23 [Abstract]
  • Lewis LK, Yandle TG, Hilton PJ, Begg EJ, Nicholls MG. Endogenous ouabain is not ouabain. Hypertension 2014; 64(4), 680-3 [Abstract]
  • Upton TJ, Hunt PJ, Doogue MP. Hyponatraemic seizure following arginine vasopressin for von Willebrand disease: pernicious, predictable and preventable. Intern Med J 2014; 44(5), 521-2 [Abstract]
  • Chin PKL, Wright DFB, Begg EJ. Dabigatran in patients with mechanical heart valves (letter). New Engl J Med 2014; 370(4), 382 [Abstract]
  • Stamp LK, Merriman TR, Barclay ML, Singh JA, Roberts RL, et al. Impaired response or insufficient dosage? Examining the potential causes of “inadequate response’ to allopurinol in the treatment of gout. Semin Arthritis Rheum 2014; 44(2), 170-4 [Abstract]
  • Buffery PJ, Allen KM, Chin PKL, Moore GA, Barclay ML, Begg EJ. Thirteen years’ experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved? Ther Drug Monit 2014; 36(1), 86-92 [Abstract]
  • Chin PKL, Wright DFB, Doogue MP, Begg EJ. Learning more from the dabigatran concentration in the RE-LY study. J Am Coll Cardiol 2014; 63(24), 2746-7 [Abstract]
  • Jensen BP, Dalrymple JM, Begg EJ. Transfer of doxazosin into breast milk (v 29, pg150, 2013). J Hum Lact 2014; 30(3), NP3-NP4 [Abstract]
  • Thynne T, Doogue M. Sodium-glucose co-transporter inhibitors: mechanisms of action. Aust Prescr 2014; 37(1), 14-16 [Abstract]
  • Doogue MP. A safe and effective drug? NZ Med J 2014; 127(1404), 6-7 [Abstract]
  • Smits A, Roberts JA, Vella-Brincat JWA, Allegaert K. Cefazolin plasma protein binding in different human populations: More than cefazolin-albumin interaction. Int J Antimicrob Agents 2014; 43(2), 199-200 [Abstract]